Investing
Bristol Myers wins dismissal of lawsuit over Celgene drugs
© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
NEW YORK (Reuters) – A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers (NYSE:) Squibb Co of defrauding investors who stood to receive $6.4 billion had it won federal approval by specified deadlines for drugs developed by the former Celgene Corp (NASDAQ:).
Read the full article here
-
Side Hustles5 days ago
The DOJ Reportedly Wants Google to Sell Its Chrome Browser
-
Side Hustles5 days ago
How to Create a Unique Value Proposition (With Tips & Examples)
-
Investing4 days ago
Are You Missing These Hidden Warning Signs When Hiring?
-
Investing6 days ago
This Founder Turned a Hangover Cure into Millions
-
Investing4 days ago
Google faces call from DuckDuckGo for new EU probes into tech rule compliance By Reuters
-
Make Money4 days ago
7 Common Things You Should Never Buy New
-
Passive Income5 days ago
How AI Can (and Should) Drive Innovation Across Your Entire Company
-
Investing5 days ago
Barbara Corcoran, Lori Greiner Differ on ‘Quiet Vacationing’